Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
  • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/43—Guanidines
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/13—Amines
  • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
  • A61K8/20—Halogens; Compounds thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
  • A61K8/34—Alcohols
  • A61K8/345—Alcohols containing more than one hydroxy group
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
  • A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
  • A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
  • A61K8/4993—Derivatives containing from 2 to 10 oxyalkylene groups
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
  • A61K8/60—Sugars; Derivatives thereof
  • A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K8/00—Cosmetics or similar toiletry preparations
  • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
  • A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
  • A61K8/84—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions otherwise than those involving only carbon-carbon unsaturated bonds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0048—Eye, e.g. artificial tears
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P27/00—Drugs for disorders of the senses
  • A61P27/02—Ophthalmic agents
  • A61P27/04—Artificial tears; Irrigation solutions
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
  • A61Q17/005—Antimicrobial preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
  • A61Q19/00—Preparations for care of the skin
  • A61Q19/10—Washing or bathing preparations
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/20—Chemical, physico-chemical or functional or structural properties of the composition as a whole
  • A61K2800/28—Rubbing or scrubbing compositions; Peeling or abrasive compositions; Containing exfoliants
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
  • A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
  • A61K2800/52—Stabilizers

Definitions

• the present invention relates to an anti-microbial composition. Further, the invention relates to compositions useful as eyelid scrubs.
• the eyelids are important to over-all ocular health because they protect the eyes from dangers such as approaching objects or from airborne contaminants, such as pollen, dust particles or other foreign bodies.
• the eyelids contain several glands including the lacrimal glands and meibomian glands that produce layers of tear film that are critical for healthy eyes.
• a new tear film is created and tears are distributed across the cornea to lubricate the surface of the eye. This blinking action also "flushes" foreign materials from the eye.
• Blepharitis is a common chronic inflammation of the eyelids characterized by a scaly crust on the lid margins. The condition may be caused by a bacterial infection, or it may be allergic in origin or associated with seborrhea of the face and scalp. Treatment usually involves cleansing the eyelids on a regular basis to remove excess oil, debris, and desquamated skin that may be problematic.
• styes infections of the tiny oil secreting meibomian glands along the edge of the eyelid, surrounding the eyelashes.
• a stye begins as a red, tender bump and usually fully develops within three days. Such conditions are accompanied by pain, redness and tenderness of the lid margins.
• chalazion is an inflammation of the meibomian glands inside the eyelid. Chalazia typically grow slowly over 2-3 weeks and although they do not typically cause pain, they often require surgical intervention if left untreated.
• Eyelid cleansers are also used for cleaning eyelashes, eyelids or the periocular area and may be used as a pre- operative scrub to help reduce the presence of harmful bacteria which may cause infection, inflammation, or even endophthalmitis in patients.
• Endophthalmitis is an intraocular infection that commonly occurs after cataract surgery.
• the causative agent in post-operative endopthalmitis is typically a bacteria, often the causative bacteria is Staphylococcus Epidermidis.
• an eyelid scrub is often used to cleanse the eyelid.
• Eyelid cleansers must be non-irritating to both the sensitive skin around the eye and the eye tissue itself, while having an antimicrobial effect.
• One factor causing eye irritation is an abnormal pH level of the eyelid cleaner composition.
• Non-irritating formulations should have a pH level which is close to neutral, 7.0.
• Many skin cleaners have a pH outside this range.
• To control the pH level of skin cleanser a traditional pH adjuster is often employed.
• Traditional pH adjusters include basic pH adjusters, such as ammonia, mono-, di- and tri-alkyl amines, mono-, di- and tri-alkanolamines, alkali metal and alkaline earth metal hydroxides (e.g., ammonia, sodium hydroxide, potassium hydroxide, lithium hydroxide, monoethanolamine, triethylamine, isopropylamine, diethanolamine and triethanolamine), and acidic pH adjusters, such as mineral acids and polycarboxylic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, citric acid, glycolic acid, and lactic acid).
• pH adjusters can also cause eye irritation themselves. Therefore, there is a need for an eyelid scrub composition which is effective at killing bacteria, but does not include traditional pH adjusters, so that it is gentle enough to be used around the eye.
• the composition of the present invention is effective as an anti-microbial, while being minimally irritating to the eye.
• the composition comprises polyhexamethylene biguanide (PHMB), 1 ,2-hexanediol, 1 ,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• PHMB polyhexamethylene biguanide
• 1 ,2-hexanediol 1 ,2-octanediol
• a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• the use of a surfactant solution to control pH rather than traditional pH adjusters makes the composition less irritating to the eye.
• the foaming capability of the surfactant solution included in the composition increases its cleansing ability.
• the pH stabilizing surfactant solution comprises cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, and a modified Ringer's solution.
• the composition also includes moisturizers, such as methyl gluceth-20, sorbital, glycerine, glycols, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid.
• the composition is produced by preparing a modified Ringer's solution by mixing electrolytes in water and mixing 1 ,2-hexanediol,1 ,2-octanediol, and an effective amount of one or more pH stabilizing surfactants with the modified Ringer's solution. The mixture is then heated and allowed to cool before polyhexamethylene biguanide is added.
• the composition may be applied to the eyelid by applying an effective amount of the composition to the eyelid.
• the composition may be rubbed onto the eyelid to induce foaming.
• the composition can be combined with a fabric pad for use as an eyelid scrub.
• the fabric pad is pre-moistened with the composition and packaged for use.
• Fig. 1 is a top view of the fabric pad of the invention.
• Fig. 2 is a top view of the container for the fabric pad.
• the composition of the invention is effective as an eyelid cleanser, or scrub, as it has an antimicrobial effect, but is still practically non-irritating to the eye.
• the composition has these beneficial characteristics because of the combination of polyhexamethylene biguanide (PHMB) and Symdiol.
• Symdiol is a combination of 1 ,2-hexanediol and 1 ,2-octanediol.
• the PHMB-Symdiol combination has a synergistic anti-microbial effect.
• the composition of this invention avoids traditional pH adjusters by using a pH stabilizing surfactant solution. Elimination of traditional pH adjusters reduces the amount of irritation caused by the composition in comparison to prior eyelid cleansers.
• the eyelid scrub composition of this invention comprises polyhexamethylene biguanide (PHMB), 1 ,2-hexanediol, 1 ,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• PHMB polyhexamethylene biguanide
• 1 ,2-hexanediol 1 ,2-octanediol
• a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• polyhexamethylene biguanide is pseudonymous for polyhexamethylene biguanide, polyhexamethylene biguanide hydrochloride, and polyaminopropyl biguanide.
• PHMB is available in a 20% aqueous solution sold under the tradename Cosmocil ® by Arch Personal Care Products L.P.
• the combination of 1 ,2-hexanediol and 1,2-octanediol is sold under the tradename Symdiol 68 by Symrise.
• 1 ,2-octanediol is also known as caprylyl glycol.
• Combining PHMB with 1 ,2-hexanediol and 1 ,2-octanediol has a synergistic antimicrobial effect.
• the pH stabilizing surfactant solution is prepared to provide a pH stabilized composition.
• Surfactants also increase cleansing ability of the composition and have a foaming capability.
• PHMB is most effective as an antimicrobial agent in pH ranges between 5.5 and 7.5. Therefore, it is desirable to control the pH level of the composition within this range by use of a blend of surfactants.
• the eyelid scrub of the present invention has a foaming ability to facilitate physical cleansing of the eyelid. Consequently, surfactants must be chosen which will both control the pH of the composition within PHMB's effective range and provide the foaming ability necessary to physically clean the eyelid.
• controlling the pH of the composition with a surfactant solution rather than traditional pH adjusters has safety benefits as many traditional pH adjusters are irritating to the eye.
• surfactants are less irritating to the eye than traditional pH adjusters.
• traditional pH adjusters include basic pH adjusters, such as ammonia, mono-, di- and tri-alkyl amines, mono-, di- and tri-alkanolamines, alkali metal and alkaline earth metal hydroxides (e.g., ammonia, sodium hydroxide, potassium hydroxide, lithium hydroxide, monoethanolamine, triethylamine, isopropylamine, diethanolamine and triethanolamine), and acidic pH adjusters, such as mineral acids and polycarboxylic acids (e.g., hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, citric acid, glycolic acid, and lactic acid).
• mineral acids and polycarboxylic acids e.g., hydrochloric acid, nitric acid, phosphoric acid
• surfactants In addition to reduced irritation, many surfactants have the added capability of producing a foam which assists in the cleansing ability of the composition.
• one or more foam producing surfactants are first chosen to provide the foaming ability of the composition. Suitable surfactants include anionic, nonionic, and amphoteric surfactants.
• both polyoxyethylene 80 sorbitan monolaurate and decyl polyglucoside are used as the foam producing surfactants.
• one or more additional surfactants may be required in the pH stabilizing surfactant solution to compensate for the pH level of the foam producing surfactants.
• a pH compensating surfactant is chosen to control the pH of the solution within the desired range. For example, if the pH level of the foam producing surfactants is in the acidic range, i.e. less that 7.0, a pH compensating surfactant in the basic range is chosen.
• Suitable pH compensating surfactants include both foaming and non-foaming surfactants, which further include anionic, nonionic, and amphoteric surfactants.
• the pH compensating surfactant is cocoamphodicetate disodium.
• a modified Ringer's solution is an isotonic aqueous solution of electrolytes which is physiologically compatible with human tissue.
• the modified Ringer's solution comprises sodium chloride, potassium chloride, calcium chloride, and water.
• Modified Ringer's solution is included in the surfactant solution to ensure that the composition will not remove water from human tissue by osmosis.
• the combination of surfactants and modified Ringer's solution are mixed with the combination of PHMB 1 1 ,2-hexanediol, and 1 ,2-octanediol to form the eyelid scrub composition.
• the pH of the entire composition, the foaming capacity of composition, and the cleansing ability of the composition are tested.
• the pH level of the composition is measured with a pH meter and the amount of the individual surfactants adjusted to control the composition's pH within the desired pH range.
• the composition's foaming capability is measured according to the Ross Miles method. This measurement involves producing foam from the composition and measuring the height and stability of the foam over time. The foam is created by pouring the composition from a set height into itself for five minutes. Alternatively, where the composition has a low foam capability, the composition is agitated with a turbine agitator for a set time to produce the foam. The thickness of the foam is measured at timed intervals. To achieve the desired foaming capability, the amounts of foam producing surfactants in the composition are varied. [0024] Finally, the cleansing capabilities of the composition are tested by anecdotal human testing. Humans apply the composition to the eyelid and cleanse the eyelid. The humans report the levels of irritation, skin tightness and overall feeling of cleanness caused by the composition. The amounts and types of surfactants employed are adjusted in response to the reports.
• pH stabilizing surfactant composition to be used is determined.
• the combination of the pH stabilizing surfactant solution with PHMB, 1,2-hexanediol and 1 ,2- octanediol forms the composition of this invention.
• the composition of this invention comprises PHMB, 1 ,2-hexanediol, and 1 ,2-octanediol in combination with a pH stabilizing surfactant solution.
• Suitable surfactants to be used in the pH stabilizing surfactant solution include amphoteric surfactants, anionic surfactants, and nonionic surfactants.
• Suitable amphoteric surfactants include, but are not limited to alkyldimethyl betaines, alkylamido betaines, sulfobetaines, and imidazoline amphoterics.
• Suitable anionic surfactants include, but are not limited to fatty alcohol sulfates, alpha olein sulfonates, sulfosuccinates, sarcosinates, phosphate esters, and carboxylates.
• Suitable nonionic surfactants include, but are not limited to alkanolamids, ethoxylate amids, esters, alxylated alcohols, alkylpolyglucosides, amine oxides, sorbitan esters, and ethoxylates.
• the pH stabilizing surfactant solution comprises cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, and a modified Ringer's solution. Cocoamphodiacetate disodium is an amphoteric surfactant. Polyoxyethylene 80 sorbitan monolaurate and decyl polyglucoside are both nonionic surfactants.
• the composition when mixed, comprises about 0.1 to 25 wt.% cocoamphodiacetate disodium, 0.1 to 10 wt.% polyoxyethylene 80 sorbitan monolaurate, 0.2 to 10 wt.% decyl polyglucoside, and 60 to 98 wt.% modified Ringer's solution.
• the modified Ringer's solution comprises, sodium chloride, potassium chloride, calcium chloride, and water.
• the water used is purified water.
• the modified Ringer's solution may also comprise 0.05 to 1.2 wt. % sodium chloride, 0.005 to 0.5 wt. % potassium chloride, 0.005 to .5 wt. % calcium chloride, and water.
• the modified Ringer's solution comprises about 0.7 wt. % sodium chloride, about 0.03 wt. % potassium chloride, about 0.033 wt. % calcium chloride, and purified water.
• the composition of this invention can further comprise one or more moisturizers.
• Moisturizers are chemicals that prevent transepidermal water loss. Moisturizers may prevent water loss by forming a film over the skin to prevent water from evaporating from the skin.
• moisturizers comprise hydroscopic molecules that draw water from the air into the skin. Suitable moisturizers include, but are not limited to, methyl gluceth-20, sorbital, glycerine, propylene glycol, carboxylates, amino acids, glucoside derivatives, urea, lactates, and derivatives of pantothenic acid. Examples of derivatives of pantothenic acid include panthenol, D-panthenol, and D 1 L- panthenol.
• the composition also comprises a foam stabilizer.
• a foam stabilizer is a chemical which increases the lifetime of the foam.
• the foam stabilizer can be a polyethylene glycol diester of methyl glucose and a fatty acid. Suitable fatty acids include oleic acid, steric acid, lauric acid, caprylic acid, and capric acid.
• the foam stabilizer is PEG-120 methyl glucose dioleate.
• composition comprises polyhexamethylene biguanide, 1 ,2-hexanediol,1 ,2-octanediol, D-panthenol, cocoamphodiacetate disodium, polyoxyethylene-80 sorbitan monolaurate, decyl polyglucoside, methyl gluceth-20, and PEG-120 methyl glucose dioleate.
• Decyl polyglucoside is sold under the tradename Oramix NS10 by Seppic, Inc.
• Polyoxyethylene-80 sorbitan monolaurate is sold under the tradename T-MAZ ® 28 by BASF Corporation.
• Cocoamphodiacetate disodium is sold under the tradename Mackam 2C by The Mcintyre Group.
• Methyl gluceth-20 is sold under the tradename Glucam ® E-20 by Dow.
• PEG-120 methyl glucose dioleate is sold under the tradename Glucamate DOE-120 by Dow.
• D-panthenol is also known as Dexpanthenol and is available from Dow.
• composition comprises about 0.02 wt.% to about 0.3 wt.% PHMB, about 0.05 wt.% to about 2.0 wt.% 1 ,2- hexanediol, about 0.05 wt.% to about 2.0 wt.% 1 ,2-octanediol, about 0.1 wt.% to about 25 wt.% cocoamphodiacetate disodium, about 0.1 wt.% to about 10 wt.% polyoxyethylene 80 sorbitan monolaurate, about 0.2 wt.% to about 10 wt.% decyl polyglucoside, and about 60 wt.% to about 98 wt.% Modified Ringer's Solution.
• composition comprises about 0.04 wt.% polyhexamethylene biguanide, about 0.2 wt.% 1 ,2-hexanediol, about 0.2 wt.% 1 ,2-octanediol, about 0.2 wt.% D-panthenol, about 0.215 wt.% cocoamphodiacetate disodium, about 4.032 wt.% polyoxyethylene 80 sorbitan monolaurate, about 0.275 wt.% decyl polyglucoside, about 4.3 wt.% methyl gluceth-20, about 0.6 wt.% PEG-120 methyl glucose dioleate, about 87.985 wt.% Modified Ringer's Solution, and water.
• Zinc salts are astringents which cause skin to tighten.
• the skin around the ocular area is more sensitive that other areas of skin.
• the inclusion of a zinc salt is a composition may be undesirable as its astringent property would make the composition more irritating to the eyelid area. Therefore in one embodiment, the composition comprises PHMB, 1 ,2-hexanediol, 1 ,2-octanediol, and a pH stabilizing surfactant solution, but is also essentially free of zinc salts.
• Examples of zinc salts include zinc acetate, zinc lactate, zinc gluconate, zinc citrate, zinc butyrate, and zinc sterate.
• the modified Ringer's solution is made by mixing electrolytes in water.
• Symdiol a combination of 1 ,2- hexanediol and1 ,2-octanediol
• the mixture is then heated to dissolve the solids into solution.
• the mixture is then allowed to cool before the polyhexamethylene biguanide is added.
• the mixture is heated to about 60° C. In another aspect, the mixture is allowed to cool until its temperature reaches about 40° C.
• the modified Ringer's solution is made by mixing sodium chloride, potassium chloride, and calcium chloride with water.
• one or more moisturizers are also added to the modified Ringer's solution.
• a foam stabilizer may also be included.
• the composition of the present invention may be used to cleanse an eyelid.
• the eyelid scrub is useful in preoperative sterilization of the eyelid and in everyday application for the prevention of various diseases of the eyelid, such as blepharitis. To cleanse the eyelid, an effective amount of the eyelid scrub is applied to the eyelid.
• the eyelid scrub comprises polyhexamethylene biguanide,1 ,2-hexanediol,1 ,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• the eyelid scrub may be rubbed on the eyelid scrub to induce foaming, which facilitates cleansing of the eyelid.
• the eyelid scrub of this invention can be mild enough that it can be allowed to remain on the eyelid after cleansing, without rinsing.
• the ability of the eyelid scrub to be left on the eyelid rather than rinsed off increases the composition's anti-microbial effect. In general, the longer an anti-microbial composition is allowed to contact the pathogens, the more pathogens it will kill.
• the eyelid scrub is applied to the eyelid from a fabric pad.
• the eyelid scrub may be rubbed on the eyelid with a fabric pad to induce foaming, which assists in the cleansing ability of the eyelid scrub.
• the composition of the present invention may be combined with a fabric pad 1 to form an apparatus for cleansing eyelids.
• the apparatus comprises a fabric pad 1 pre-moistened with an eyelid scrub composition.
• the eyelid scrub composition comprising polyhexamethylene biguanide, 1 ,2-hexanediol,1 ,2-octanediol, and a pH stabilizing surfactant solution present in an amount effective to control the pH level of the composition between 5.5 and 7.5.
• the fabric pad 1 comprises a rayon and polypropylene fabric blend.
• the fabric pad comprises a textured surface 2.
• the apparatus further comprises a sealable container 3 enclosing the pre-moistened fabric pad.
• the sealable container 3 may comprise a box, or a package.
• the package may be made of any suitable material including plastic or a metal foil material.
• the pre-moistened fabric pads may be individually packaged for use.
• the apparatus comprises 1.3 to 1.5 grams of eyelid scrub. Preferably, the 1.4 grams of eyelid scrub are used.
• composition of the present invention has an anti-microbial effect with a lower level on irritation than other antimicrobial compositions. To confirm the characteristic of the composition of this invention both the irritation and antimicrobial effects of the composition were tested. These results were compared to another commonly available composition, Sterelid®. [0042] One embodiment of the composition of this invention was tested for both irritation and anti-microbial effect, hereafter referred to as Composition 1.
• Composition 1 contained polyhexamethylene biguanide, 1 ,2-hexanediol, 1 ,2- octanediol, D-panthenol, cocoamphodiacetate disodium, polyoxyethylene 80 sorbitan monolaurate, decyl polyglucoside, methyl gluceth-20, PEG-120 methyl glucose dioleate, Modified Ringer's Solution, and water.
• Sterilid® available from Advanced Vision, contains water, PEG-80, sorbitan laurate, sodium trideceth sulfate, cocamidopropyl betaine, sodium lauroamphacetate, PEG-150 distearate, sodium laureth -13 carboxylate, linalool oil, hepes acetate, sodium perborate monohydrate, panthenol, allantoin, sodium chloride, tea tree oil, Tris-EDTA, boric acid, cocamidopropyl PG-dimonium chloride, etidronic acid, phosphonic acid, with citric acid and sodium hydroxide for pH adjustment.
• Composition Mean Irritation Score Composition 1 1.67/110.0
• Both Composition 1 and Sterilid were also subjected to time-kill studies to determine their effectiveness against the pathogen Staphylococcus Epidermidis (S. Epidermidis), which is a leading cause of post-operative endophthalmitis, a type of post-operative infection.
• the time-kill testing involved subjecting a suspension of the pathogen to the composition for 60 seconds and then neutralizing the composition. The pathogen was then plated and incubated for the appropriate amount of time. After incubation, the number of colonies of the pathogen were counted and the logarithmic reduction (Log Reduction) of the colony count from the control's colony count was calculated.
• the results of the time-kill study are presented in Table 2. Table 2
• Composition 1 was found to have a Log reduction of 5.5 of S. Epidermidis., while Sterilid was found to have Log reduction of 3.5 of S. Epidermidis. Composition 1's ability to kill the S. Epidermidis pathogen was therefore greater that Sterilid's.
• composition 1 was both more effective and less irritating than Sterilid, which uses citric acid and sodium hydroxide for pH adjustment rather than the pH modifying surfactant solution of the present invention.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• General Health & Medical Sciences (AREA)
• Epidemiology (AREA)
• Birds (AREA)
• Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Dermatology (AREA)
• Ophthalmology & Optometry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Emergency Medicine (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Inorganic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Engineering & Computer Science (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Detergent Compositions (AREA)
• Cosmetics (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Medicinal Preparation (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Devices For Medical Bathing And Washing (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39223072

Family Applications (1)

Country Status (7)

Cited By (2)

Families Citing this family (17)

Family Cites Families (30)

• 2006
  • 2006-11-03 US US11/592,684 patent/US7951387B2/en active Active
• 2007
  • 2007-11-02 EP EP07853075.5A patent/EP2086498B1/en active Active
  • 2007-11-02 JP JP2009535335A patent/JP4981143B2/ja active Active
  • 2007-11-02 KR KR1020097010827A patent/KR101216566B1/ko active Active
  • 2007-11-02 CN CN200780041024XA patent/CN101583341B/zh active Active
  • 2007-11-02 AU AU2007317907A patent/AU2007317907B2/en active Active
  • 2007-11-02 WO PCT/US2007/023183 patent/WO2008057442A2/en not_active Ceased
• 2010
  • 2010-09-03 AU AU2010100970A patent/AU2010100970A4/en not_active Expired

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events